A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: The spanish Earth-1 study

AIDS

Volumn 13, Issue 17, 1999, Pages 2377-2388

  García, Felipe ^a   Romeu, Joan ^b   Grau, Inmaculada ^c   Sambeat, María Antonia ^d   Dalmau, David ^e   Knobel, Hernado ^f   Gomez Sirvent, Juan Luis ^g   Arrizabalaga, Julio ^h   Cruceta, Anna ^a   Clotet, Bonaventura ^b   Podzamczer, Daniel ^c   Pumarola, Tomás ^a   Gallart, Teresa ^a   O'Brien, William A ⁱ   Miró, José M ^a   Gatell, José M ^a   Vidal, C ^c   Plana, M ^c   Blanch, J L ^c   Tortajada, C ^c   Gil, C ^c   Ortega, M ^c   Soriano, A ^c   Niebla, G ^c   Maleno, M J ^c   Caballero, M ^c   Rivalta, T ^c   Palou, E ^c   Barcelo J J ^c   Mejias T ^c   Mallolas, J ^c   Martinez E ^c   Ruiz, L ^b   Puig, T ^b   Negredo, E ^d   Martinez Lacasa, X ^e   Sanjaume, M ^e   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL MÚTUA DE TERRASSA   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^h Hospital Nuestra Senora de Aranzazu   (Spain)

ⁱ University of Texas Medical Branch School of Medicine   (United States)

Author keywords

AIDS; Antiretroviral therapy; CD4 cell count; HIV; HIV RNA; Immune restoration; Viral load

Indexed keywords

CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; MITOGENIC AGENT; RITONAVIR; STAVUDINE; VIRUS ANTIGEN; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CELL PROLIFERATION; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DEATH; DIGESTIVE SYSTEM FUNCTION DISORDER; DISEASE SEVERITY; FEMALE; GENOTYPE; HEADACHE; HEPATITIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; LYMPHOID TISSUE; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; NONHUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICS; VIRUS LOAD; VOMITING;

EID: 0032785582     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199912030-00009     Document Type: Article

References (48)

1. Gazzard B, Moyle G. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee. Lancet 1998, 352:314-316.
2. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. ] Am Med Assoc 1998,280:78-86.
3. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Ann Intern Med 1998, 128:1079-1100.
4. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and sérologie markers in infection with human immunodeficiency virus type 1. N Engl I Med 1990, 322:166-172.
5. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997, 126:946-954.
6. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodefieciency virus infection and prior antiretroviral therapy. N Engl J Med 1997, 337:734-739.
7. O'Brien VVA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Croup on AIDS. N Engl] Med 1996, 334:426-431.
8. O'Brien VVA, Hartigan PM, Daar ES, Simberoff MS, Hamilton JD. Changes in plasma H1V RNA Levels and CD4 + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann Intern Med 1997, 126:939-945.
9. Katzenstein DA, Hammer SM, Hughes MD, et aJ. The relation of virologie and immunologie markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Croup Study 175 Virology Study Team (see comments]. N Engl ] Med 1996,335:1091-1098.
10. Brun-Vezinet F, Boucher C, Loveday C, et al. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Croups. Delta Virology Working Croup and Coordinating Committee [see comments], lancet 1997, 350:983-990.
11. Montaner JSC, Montessori V, Raboud JM, et al. How low is low enough? Suppression of plasma viral load below 20 copies/ml is necessary for long term virologie response. XII international Conference on AIDS. Geneva, June 1998 [abstract 12364].
12. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Croup 320 Study Team [see comments]. N Engl J Med 1997, 337:725-733.
13. Delta Coordinating Committee. Delta: a randomised doubleblind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIVinfected individuals, lancet 1996, 348:283-291.
14. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIVinfected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl] Med 1996, 335:1099-1106.
15. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monolherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubi millimeter. N Engl] Med 1996, 335:1081-1090.
16. Fischl MA, Richman DD, Crieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl] Med 1987, 317:185-191.
17. Fischl MA, Richman DD, Hansen N. The safety and efficacy of zidovudine (AZT) in the treatment of mildly symptomatic human immunodeficiency virus type 1 (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990, 112:727-737.
18. Volberding PA, Lagakos SVV, Koch MA. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl ] Med 1990, 322:941-949.
19. Hamilton JD, Hartigan PM, Simberoff MS, et al. Early versus later zidovudine therapy for patients with symptomatic human immunodeficiency virus infection: results of a randomized, double-blind VA cooperative study. N Engl ] Med 1992, 326:437-443.
20. Simberkoff MS, Hartigan PM, Hamilton JD, et al. Long-term follow-up of symptomatic HIV-infected patients originally randomized to early versus later zidovudine treatment; report of a Veterans Affairs Cooperative Study. VA Cooperative Study Croup on AIDS Treatment. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 11:142-150.
21. Volberding PA, Lagakos SW, Crimes JM, et al. A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Croup. N Engl ] Med 1995, 333:401-407.
22. Concorde Coordinating Commitee. Concorde MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection, lancet 1994,343:871-881.
23. Cooper D, Gatell JM. Zidovudine in asymptomatic HIV infection. N EnglJ Med 1993, 329:1895-1896.
24. loannidis JP, Cappelleri JC, Lau J, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDSdefining illness. Ann Intern Med 1995, 122:856-866.
25. Centers for Disease Control. Update: acquired immunodeficiency syndrome - United States, 1992. MMWR 1993, 42:547-551; 557.
26. Division of AIDS. Division of AIDS Table for Grading Severity of Adult Adverse Experiences. Rockville, MD: National Institute of Allergy and Infectious Diseases; 1996.
27. Boom R, Sol CJA, Salimans MMM, Jansen CL, Wertheim-van Dillen PME, van der Noordaa J. Rapid and simple method for purification of nucleic acids, j Clin Microbiol 1990, 28:495-503.
28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987; 162:156-9
29. Finzi D, Hermankova M, Pierson T, et aJ. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997, 278:1295-1300.
30. Notermans DVV, Jurriaans S, de Wolf F, et aJ. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Croup. AIDS 1998, 12:167-173.
31. Tenner-Racz K, Stellbrink HJ, van Lunzen, J, et al. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapyj Exp Med 1998, 187:949-959.
32. Lafeuillade A, Tamalet C, Poggi C, et al. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes. AIDS 1997, 11:67-72.
33. Harris M, Durakovic C, Rae S, et al. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J Infect Dis 1998, 177:1514-1520.
34. Cunthard H, VVong J, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. ) Virol 1998, 72:2422-2428.
35. Kempf DJ, Rode RA, Xu Y, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998, 12:F9-F14.
36. Yu G, Clendeninn NJ, Quart B, Greenberg L, Chang Y. Viral load levels during treatment with Viracept combination treatment as predictor of response and guidance for treatment choice strategy. XII international Conference on AIDS. Geneva, June, 1998 [abstract 12300].
37. Gulick RM, Mellors JVV, Havlir D, et aJ. Simultaneous versus sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection: 100 week follow-up, y Am Med Assoc 1998, 280:35-41.
38. Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, Kovacs JA. HIV-1 replication in patients with undelectable plasma virus receiving HAART, iancet 1999, 353:119-120.
39. Autran B, Carcelain C, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
40. Levy JA. Caution: should we be treating HIV infection early? Lancet 1998, 352: 982-983.
41. Plana M, Garcia F, Gallart T, Miro JM, Gatell JM. Lack of T-cell proliferative response to HIV-1 antigens after 1 year of highly active anliretroviral treatment in early HIV-1 disease. Lancet 1998,352:1194-1195.
42. Angel J, Kurriar A, Parato K, et al. Improvement in cellmediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998, 177:898-904.
43. Mocroft A, Bofill M, Lipman M, et al. CD8+,CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. ! Acquir Immune Defic Syndr Hum Retrovirol 1997, 14:158-162.
44. Liu SL, Schacker T, Musey L, et aJ. Divergent patterns of progression to AIDS after infection from the same. J Virol 1997, 71:4284-4295.
45. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998, 351:867-870.
46. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875.
47. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 352:1881-1883.
48. Martînez E, Gatell JM. Metabolic abnormalities and use of HIV-lprotease inhibitors. Lancet 1998, 352: 821-822.